Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by ...

DexCom faces challenges in 2024 due to competition and missteps, but the long-term outlook for continuous glucose monitors ...

Tandem Diabetes Care announced today that t:slim X2 insulin pump users in Canada can now access full compatibility with ...

(Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being worn by ...

DexCom (NASDAQ:DXCM – Get Free Report) had its target price increased by stock analysts at Canaccord Genuity Group from $89.00 to $99.00 in a research report issued to clients and investors on Monday, ...

Rebate dynamics: An accelerated shift from G6 to G7 products resulted ... The launch of Stelo CGM represents a significant opportunity for DexCom to expand its market reach and accelerate growth.

Rebate dynamics: An accelerated shift from G6 to G7 products resulted in increased rebates paid to U.S ... and its ability to maintain its leadership position in the CGM market. The launch of Stelo ...

Dexcom Inc是一家医疗设备公司。该公司主要专注于连续血糖监测(CGM)系统的设计、开发和商业化，供糖尿病患者和医疗保健提供者使用。其Dexcom G6是一种CGM 系统，可作为集成系统的一部分与其他兼容的医疗设备和电子接口一起使用，其中可能包括自动胰岛素剂量 ...